Fluconazole and Topical Therapy Recommendations for Pediatric Vaginal Candidiasis

Treatment Recommendations

The Infectious Diseases Society of America (IDSA) 2016 guideline recommends a single 150‑mg oral dose of fluconazole for uncomplicated vulvovaginal candidiasis, citing strong evidence from high‑quality studies. 1
The IDSA 2016 guideline states that topical azole creams or nystatin are equally effective first‑line alternatives, with no single topical agent shown to be superior. 1
According to the IDSA 2016 guideline, the choice between oral fluconazole and topical therapy should be guided by practical considerations: oral therapy offers superior convenience and compliance, whereas topical therapy may be preferred in very young children or when systemic absorption is a concern. 1

For severe acute vulvovaginitis, the IDSA 2016 guideline advises fluconazole 150 mg administered every 72 hours for a total of 2–3 doses rather than a single dose. 1
For recurring vulvovaginal candidiasis, the IDSA 2016 guideline recommends an induction course of 10–14 days followed by fluconazole 150 mg weekly for 6 months. 1
Weekly maintenance therapy reduces recurrence dramatically, with 90.8 % of patients remaining disease‑free at 6 months versus 35.9 % with placebo (p < 0.001). This outcome is reported in the IDSA 2016 guideline. 1

The IDSA 2016 guideline cautions against the use of systemic ketoconazole in pediatric patients because of FDA/EMA warnings regarding hepatotoxicity, adrenal suppression, and drug interactions. 1

The IDSA 2016 guideline emphasizes that proper diagnosis must be confirmed before treatment, as vaginal candidiasis in prepubertal children may warrant investigation for predisposing factors or alternative diagnoses. 1

The Clinical Infectious Diseases 2009 article notes that if a patient has recently received azole prophylaxis, azole resistance may be present, although resistance is uncommon with Candida albicans. 2

The American Academy of Pediatrics and the Infectious Diseases Society of America recommend fluconazole 8-12 mg/kg once daily as the first-line systemic agent for invasive candidiasis in pediatric patients 3, 4
For suspected invasive or systemic fungal infections, voriconazole 9 mg/kg twice daily or itraconazole suspension 2.5 mg/kg twice daily should be used with therapeutic drug monitoring, as recommended by the European Society of Clinical Microbiology and Infectious Diseases 4, 5

For invasive candidiasis, the Infectious Diseases Society of America recommends fluconazole 8-12 mg/kg IV or orally once daily 3, 4
For suspected aspergillosis or mold infection, the European Society of Clinical Microbiology and Infectious Diseases recommends voriconazole 9 mg/kg BID with TDM (target trough ≥1 mg/L) 4, 5
For immunocompromised patients, such as those with hematopoietic stem cell transplant or leukemia, the Infectious Diseases Society of America recommends considering micafungin 1 mg/kg IV daily or itraconazole 2.5 mg/kg twice daily with TDM (target trough ≥0.5 mg/L) 3, 4, 5

Alternative topical agents for superficial skin infections include clotrimazole or miconazole if sertaconazole is unavailable, as suggested by the American Academy of Dermatology 6
The American Academy of Pediatrics advises against using systemic ketoconazole in pediatric patients due to FDA/EMA warnings regarding hepatotoxicity, adrenal suppression, and drug interactions, and extends this principle to avoiding systemic use of any topical-only azole 7
For vaginal candidiasis in prepubertal children, the American Academy of Pediatrics recommends topical nystatin or azole creams as first-line treatment, rather than sertaconazole suppositories which are designed for postpubertal patients 6